1-(1-methyl-2-propoxyethoxy)propan-2-ol

Endpoint summary

Key value for chemical safety assessment

Skin sensitisation

Link to relevant study records

Reference

Endpoint:

skin sensitisation: in vivo (non-LLNA)

Type of information:

experimental study

Adequacy of study:

key study

Study period:

2004

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

other: GLP-study according to OECD Guideline 406, U.S. EPA OPPTS 870.2600 (2003), and EU Guideline 92/69, Annex V, B6 (1992)

Reason / purpose for cross-reference:

reference to same study

Reason / purpose for cross-reference:

reference to other study

Qualifier:

according to guideline

Guideline:

OECD Guideline 406 (Skin Sensitisation)

Principles of method if other than guideline:

not applicable

GLP compliance:

yes

Type of study:

Buehler test

Justification for non-LLNA method:

This substance has been demonstrated to be a non-sensitizer in a guideline compliant studies, therefore potency data as generated in an LLNA is not needed.

Species:

guinea pig

Strain:

Hartley

Sex:

male/female

Details on test animals and environmental conditions:

Upon arrival, all animals were housed in individual suspended wire-mesh cages.

The basal diet and municipal water, delivered by an automatic watering system, were provided ad libitum.

The animal room was maintained with controlled temperature, humidity and light (12 hours light/12 hours dark). The room temperature and humidity controls were set to maintain daily averages of 66 ± 5°F (19 ± 3°C) and 50 ± 20% relative humidity.

Actual mean daily temperature ranged from 65.5°F to 67.4°F (18.6°C to 19.7°C) and mean daily relative humidity ranged from 26.2% to 92.4%
during the study.

Route:

epicutaneous, occlusive

Vehicle:

unchanged (no vehicle)

Concentration / amount:

Test material was applied undiluted.

Route:

epicutaneous, occlusive

Vehicle:

unchanged (no vehicle)

Concentration / amount:

Test material was applied undiluted.

No. of animals per dose:

10/sex
5/sex (negative controls)

Details on study design:

INDUCTION PHASE:
The test article, undiluted ARCOSOLV® DPnP, was administered at 0.3 mL/site. Doses were applied under 25-mm Hill Top Chambers®, occluded with plastic wrap and overwrapped with nonirritating elastic tape. Induction doses were applied to the same site on the anterior left flank of all Test Group animals. Test Group animals received three induction doses spaced one week apart over a period of three weeks. All induction exposures were six hours, after which the bandages were removed and the sites wiped with disposable paper towels moistened with tepid tap water. Naive Control-I Group animals remained untreated during the Induction Phase.

CHALLENGE PHASE:
The Challenge Phase consisted of a single application of the maximal nonirritating concentration of test article to determine if delayed contact hypersensitivity had occurred. Two weeks after the final induction dose, an undiluted concentration of the test article, ARCOSOLV® DPnP, was administered to unexposed sites on the posterior left flank of the Test and Naive Control-I Group animals at 0.3 mL/site. Doses were applied under 25-mm Hill Top Chambers® that were occluded with plastic wrap and overwrapped with nonirritating elastic tape. All challenge exposures were six hours, after which the bandages were removed and the sites wiped with disposable paper towels moistened with tepid tap water.

Challenge controls:

Naive Control-I Group animals remained untreated during the Induction Phase.

Positive control substance(s):

no

Positive control results:

None

Reading:

1st reading

Hours after challenge:

24

Group:

test chemical

Dose level:

0.3 mL

No. with + reactions:

0

Total no. in group:

20

Clinical observations:

None

Remarks on result:

other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 0.3 mL. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: None.

Reading:

2nd reading

Hours after challenge:

48

Group:

test chemical

Dose level:

0.3 mL

No. with + reactions:

0

Total no. in group:

20

Clinical observations:

None

Remarks on result:

other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 0.3 mL. No with. + reactions: 0.0. Total no. in groups: 20.0. Clinical observations: None .

Reading:

1st reading

Hours after challenge:

24

Group:

negative control

Dose level:

0

No. with + reactions:

0

Total no. in group:

10

Clinical observations:

None

Remarks on result:

other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: None.

Reading:

2nd reading

Hours after challenge:

48

Group:

negative control

Dose level:

0

No. with + reactions:

0

Total no. in group:

10

Clinical observations:

None

Remarks on result:

other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 0. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: None.

Group:

positive control

Remarks on result:

not measured/tested

None

Interpretation of results:

not sensitising

Remarks:

Migrated information Criteria used for interpretation of results: EU

Conclusions:

Under the conditions of this study, ARCOSOLV® DPnP did not cause skin sensitization in albino guinea pigs.

Executive summary:

The sensitization potential of ARCOSOLV® DPnP was evaluated in this modified Buehler method dermal sensitization study. A Test Group of 10 male and 10 female Hartley albino guinea pigs was dosed topically with the test article one time per week for three weeks for a total of three induction exposures. The duration of each exposure was six hours. Two weeks after the last induction exposure, the animals were challenge-dosed for detection of sensitization by topical application of the test article to previously unexposed areas of skin. A Naive Control-I Group of 5 male and 5 female guinea pigs was dosed with the test article at challenge in the same manner as the Test Group and served as an irritation control. Reactions to challenge dosing were evaluated at approximately 24 and 48 hours after completion of exposure. Body weights and clinical observations were recorded at randomization (study day -1) and at study termination (study day 30).

Positive control data were not generated as part of this study. WIL historical positive control data from a study conducted within six months of this test were used to demonstrate the reliability of the experimental design.

There were no deaths, test article-related clinical findings or remarkable body weight changes during the study period. Following challenge dosing with ARCOSOLV® DPnP, there were no significant dermal reactions in the Test or the Naive Control Groups. The Incidence Index for the Test Group was 0% (0/20) following challenge dosing.

Under the conditions of this study, ARCOSOLV® DPnP was a non-sensitizer in albino guinea pigs.

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed (not sensitising)

Additional information:

The sensitization potential of ARCOSOLV® DPnP was evaluated in this modified Buehler method dermal sensitization study. A test group of 10 male and 10 female Hartley albino guinea pigs was dosed topically with the test article one time per week for three weeks for a total of three induction exposures. The duration of each exposure was six hours. Two weeks after the last induction exposure, the animals were challenge-dosed for detection of sensitization by topical application of the test article to previously unexposed areas of skin. A Naive Control-I Group of 5 male and 5 female guinea pigs was dosed with the test article at challenge in the same manner as the Test Group and served as an irritation control. Reactions to challenge dosing were evaluated at approximately 24 and 48 hours after completion of exposure. Body weights and clinical observations were recorded at randomization (study day -1) and at study termination (study day 30).

There were no deaths, test article-related clinical findings or remarkable body weight changes during the study period. Following challenge dosing with ARCOSOLV® DPnP, there were no significant dermal reactions in the Test or the Naive Control Groups. The Incidence Index for the Test Group was 0% (0/20) following challenge dosing.

Under the conditions of this study, ARCOSOLV® DPnP was a non-sensitizer in albino guinea pigs.

Migrated from Short description of key information:
Skin sensitization study in guinea pigs

Justification for selection of skin sensitisation endpoint:
Only study available for the endpoint - well gonducted according to the guideline.

Respiratory sensitisation

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information:

Based on the absence of skin sensitising potential, genotoxicity and irritancy, dipropylene glycol n-propyl ether is not expected to be a respiratory tract sensitiser.

Migrated from Short description of key information:
There are no respiratory sensitization studies avaialble for dipropylene glycol n-propyl ether

Justification for classification or non-classification

Based on the results of the study and Guidance to Regulation (EC) No. 1272/2008 on Classification, Labelling and Packaging of substances and mixtures, dipropylene glycol n-propyl ether will not be classified as a skin or a respiratory sensitizer.